Sam Tsimikas/X
Aug 23, 2025, 08:14
Sam Tsimikas: NAFCS Score as a Diagnostic Tool for Familial Chylomicronemia Syndrome in Clinical Practice
Sam Tsimikas, Professor of Medicine at the University of California, San Diego, shared a post on X:
“A new paper is out in Lipid Journal validating the NAFCS score for patients with FCS (Familial Chylomicronemia Syndrome- i.e milky plasma) using the Balance genetic data. It will be an alternative method to make the diagnosis of FCS clinically.”
Read the full paper here.
Article: Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study
Authors: Alan S. Brown, Philippe Moulin, Andrew Dibble, Veronica J. Alexander, Lu Li, Daniel Gaudet, Joseph L. Witztum, Sotirios Tsimikas, Robert A.

Stay updated with Hemostasis Today.
Alan S. Brown
Andrew Dibble
Cardiometabolic Health
Chylomicronemia Syndrome
Clinical Validation
Daniel Gaudet
FCS
Genetic Diagnosis
Health
Hematology
Hemostasis Today
Joseph L. Witztum
Lipid Research
LipidJournal
Lu Li
Medicine
NAFCS
Philippe Moulin
Rare Disorders
Robert A.
Sotirios Tsimikas
Veronica J. Alexander
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial